Alzheimer's disease (AD), the most common form of dementia, is the sixth-leading cause of death in the US. The disease affects ~5 million Americans, and had a care cost of ~$200 billion in 2012. Despite extensive investigation of AD pathogenesis and tremendous investment in developing therapeutics for AD, no cure is available for the disease. Thus, there is an urgent need to accelerate research to develop effective treatments for AD. Deposition of protein aggregates is a common feature of AD pathology. Identification of the aggregated proteins, together with genetic studies, can provide crucial insights into the molecular pathogenesis of AD. The resulting amyloid cascade and tau hypotheses dominate AD studies, but their interpretation has been evolving and soluble protein oligomers emerge as toxic species. However, AD etiology remains to be fully illustrated. We previously performed a comprehensive study of the human brain aggregated proteome by mass spectrometry and identified 4,216 proteins, among which 36 proteins accumulate in AD, including U1-70K and other U1 small nuclear ribonucleoprotein (U1 snRNP) spliceosome components. Multiple U1 snRNP subunits form cytoplasmic tangle-like structures in AD but not in other neurodegenerative disorders [e.g., Parkinson's disease, frontotemporal lobar degeneration, and corticobasal degeneration (with tauopathy)], indicating that U1 snRNP pathology is AD specific and cannot be induced by tauopathy alone. Deep RNA sequencing revealed global dysregulation of RNA processing in AD brain. Importantly, U1-70K aggregation was found in mild cognitive impairment and early Braak stages of AD, indicating that U1 snRNP alteration occurs early in AD development. U1 snRNP components also aggregate in early onset genetic forms of AD cases with PS1 and APP mutations as well as trisomy 21, suggesting that abnormal amyloid cascade may cause U1 snRNP dysfunction in human. Interestingly, U1-70K knockdown or antisense oligonucleotide inhibition of U1 snRNP increased the level of amyloid precursor protein (APP) and A production in cellular models and possibly in a mouse model, suggesting a vicious cycle of A production and U1 snRNP abnormality. Thus, our hypothesis is that U1 snRNP dysfunction can mediate neurodegeneration and modulate A production, contributing to AD pathogenesis. We will test this hypothesis in three specific aims: (i) investigate whether U1 snRNP dysfunction leads to neurotoxicity in cellular models; (ii) examine whether U1 snRNP dysfunction leads to neurodegeneration in a mouse model; and (iii) determine how U1 snRNP dysfunction causes aberrant A production. Our results will illustrate the potential role of RNA splicing dysfunction in AD pathogenesis, which may lead to the development of novel strategies to effectively diagnose and treat this disease.

Public Health Relevance

Alzheimer's disease is the sixth leading cause of death in the United Sates, affecting ~5.4 million Americans, but there is no cure for the disease. We propose to investigate the role of RNA splicing dysfunction in the development of Alzheimer's disease. The study will provide important insights into molecular mechanisms of pathogenesis, which may offer new strategies for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG047928-01A1
Application #
8886742
Study Section
Cellular and Molecular Biology of Neurodegeneration Study Section (CMND)
Program Officer
Miller, Marilyn
Project Start
2015-05-01
Project End
2020-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$369,205
Indirect Cost
$127,920
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Du, Xingrong; Wen, Jing; Wang, Yanyan et al. (2018) Hippo/Mst signalling couples metabolic state and immune function of CD8?+ dendritic cells. Nature 558:141-145
Zeng, Hu; Yu, Mei; Tan, Haiyan et al. (2018) Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis. Sci Adv 4:eaar5701
Stewart, Elizabeth; McEvoy, Justina; Wang, Hong et al. (2018) Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell 34:411-426.e19
Wang, Xusheng; Jones, Drew R; Shaw, Timothy I et al. (2018) Target-Decoy-Based False Discovery Rate Estimation for Large-Scale Metabolite Identification. J Proteome Res 17:2328-2334
Wang, Zhiqiang; Ma, Jing; Miyoshi, Chika et al. (2018) Quantitative phosphoproteomic analysis of the molecular substrates of sleep need. Nature 558:435-439
Shen, Jianqiao; Pagala, Vishwajeeth R; Breuer, Alex M et al. (2018) Spectral Library Search Improves Assignment of TMT Labeled MS/MS Spectra. J Proteome Res 17:3325-3331
Wang, Zhi-Hao; Wu, Wanqiang; Kang, Seong Su et al. (2018) BDNF inhibits neurodegenerative disease-associated asparaginyl endopeptidase activity via phosphorylation by AKT. JCI Insight 3:
Xie, Boer; Wang, Yuanyuan; Jones, Drew R et al. (2018) Isotope Labeling-Assisted Evaluation of Hydrophilic and Hydrophobic Liquid Chromatograph-Mass Spectrometry for Metabolomics Profiling. Anal Chem 90:8538-8545
Bai, B; Tan, H; Pagala, V R et al. (2017) Deep Profiling of Proteome and Phosphoproteome by Isobaric Labeling, Extensive Liquid Chromatography, and Mass Spectrometry. Methods Enzymol 585:377-395
Bai, Bing; Tan, Haiyan; Peng, Junmin (2017) Quantitative Phosphoproteomic Analysis of Brain Tissues. Methods Mol Biol 1598:199-211

Showing the most recent 10 out of 19 publications